The loss of APE1 diminishes the melanoma cells’ ability to repair reactive oxygen species (ROS)‐induced DNA damage, thereby increasing their resistance to targeted therapy, such as vemurafenib.[78] Aging also influences melanoma progression by modulating lipid metabolism within the TME. Here, APEX1 is linked to melanoma.